Biohit Oyj   Report issue

For profit Phase 2
Founded: Helsinki Finland (1988)
Status: No NME R&D (1988)

Organization Overview

First Clinical Trial
2012
NCT02524262
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Biohit Oyj, Helsinki, Finland

Active Ingredients

Drugs in Phase 2 Trials (1)

l-cysteine (cysteine hydrochloride) (1 trial)

Drugs in Other Trials (1)

acetium (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Gastritis (Phase 2)

Gastritis, Atrophic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2